N-(5-amino-2-cyclopropylphenyl)acetamide → N-[5-[[3-cyano-7-(oxetan-3-ylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-cyclopropylphenyl]acetamide
反応式
CC(=O)Nc1cc(N)ccc1C1CC1.N#Cc1cnn2c(NC3COC3)cc(Cl)nc12>CC(=O)N(C)C.CC(C)c1cc(C(C)C)c(-c2ccccc2P(C(C)(C)C)C(C)(C)C)c(C(C)C)c1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd].[Pd]>CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)ccc1C1CC1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 150 °C
実験手順
A 10 mL microwave reactor vial was charged with 5-chloro-7-(oxetan-3-ylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (80 mg, 0.32 mmol), N-(5-amino-2-cyclopropylphenyl)acetamide (67.1 mg, 0.35 mmol), Cs2CO3 (313 mg, 0.96 mmol), Pd2(dba)3 (14.67 mg, 0.02 mmol) and 2-Di-t- butylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl (13.61 mg, 0.03 mmol). The suspended in DMA (.5 mL), added via syringe. The resulting brown suspension was stirred under nitrogen, then microwave vial capped and heated at 150 °C under microwave irradiation for 20 min. LCMS indicated formation of product. The cooled reaction mixture was put through vacuum filtration and concentrated in rotovap. The crude material was purified by ISCO using MeOH and EtOAc (1:10). The solid was suspended in water, stirred for 12 h at rt, repurified with EtOAc, collected and dried to afford a light brown powder (9 mg, 6%) at 93% purity. LCMS, HPLC, and HNMR consistent with desired product- see attached.
出典と根拠
- ORDレコード
- ord-a242bdcea6fd4820b97f40b83c063cc9
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
反応ノート
読み込み中…